Who makes GR37547 tablet?

GR37547 tablet is developed by GlaxoSmithKline.

Last reviewed 2026-04-19 · How we verify

GR37547 tablet

GlaxoSmithKline · Phase 1 active Small molecule

At a glance

Generic name	GR37547 tablet
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GR37547 tablet CI brief — competitive landscape report
GR37547 tablet updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI